Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (original) (raw)

• Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE . (2005). BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 4: 1303–1310.
  Article CAS PubMed Google Scholar
• Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS et al. (2005). Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534–2543.
  Article CAS PubMed Google Scholar
• Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y et al. (2005). Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37: 1038–1040.
  Article CAS PubMed Google Scholar
• Arslan MA, Kutuk O, Basaga H . (2006). Protein kinases as drug targets in cancer. Curr Cancer Drug Targets 6: 623–634.
  Article CAS PubMed Google Scholar
• Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D et al. (2005). Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92: 1855–1861.
  Article CAS PubMed PubMed Central Google Scholar
• Bain J, McLauchlan H, Elliott M, Cohen P . (2003). The specificities of protein kinase inhibitors: an update. Biochem J 371: 199–204.
  Article CAS PubMed PubMed Central Google Scholar
• Baselga J, Arteaga CL . (2005). Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445–2459.
  Article CAS PubMed Google Scholar
• Basso AD, Kirschmeier P, Bishop WR . (2006). Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47: 15–31.
  Article CAS PubMed Google Scholar
• Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M et al. (2006). Validating cancer drug targets. Nature 441: 451–456.
  Article CAS PubMed Google Scholar
• Bergo MO, Ambroziak P, Gregory C, George A, Otto JC, Kim E et al. (2002). Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol 22: 171–181.
  Article CAS PubMed PubMed Central Google Scholar
• Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ et al. (2004). Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 113: 539–550.
  Article CAS PubMed PubMed Central Google Scholar
• Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Gomes et al. (2001). Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem 276: 5841–5845.
  Article CAS PubMed Google Scholar
• Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Young SG . (2000). Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J Biol Chem 275: 17605–17610.
  Article CAS PubMed Google Scholar
• Bier H, Hoffmann T, Haas I, van Lierop A . (1998). Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46: 167–173.
  Article CAS PubMed Google Scholar
• Bodart JF, Chopra A, Liang X, Duesbery N . (2002). Anthrax, MEK and cancer. Cell Cycle 1: 10–15.
  Article CAS PubMed Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.
  Article CAS PubMed Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643–655.
  Article CAS PubMed Google Scholar
• Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A et al. (2006). Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79: 129–135.
  Article CAS PubMed PubMed Central Google Scholar
• Cheng KW, Lahad JP, Gray JW, Mills GB . (2005). Emerging role of RAB GTPases in cancer and human disease. Cancer Res 65: 2516–2519.
  Article CAS PubMed Google Scholar
• Citri A, Skaria KB, Yarden Y . (2003). The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54–65.
  Article CAS PubMed Google Scholar
• Clarke S, Tamanoi F . (2004). Fighting cancer by disrupting C-terminal methylation of signaling proteins. J Clin Invest 113: 513–515.
  Article CAS PubMed PubMed Central Google Scholar
• Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS . (2003). Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 63: 5669–5673.
  CAS PubMed Google Scholar
• Cortes J, Baselga J, Kellokumpu-Lehtinen P, Bianchi G, Cameron D, Miles D et al. (2005). Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. ASCO Meeting Abstracts 22 (16S) (abstract 3068).
• Cox AD, Der CJ . (2002a). Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2: 388–393.
  Article CAS PubMed Google Scholar
• Cox AD, Der CJ . (2002b). Ras family signaling: therapeutic targeting. Cancer Biol Ther 1: 599–606.
  Article CAS PubMed Google Scholar
• Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT et al. (2002). Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 8: 2188–2192.
  CAS PubMed Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.
  Article CAS PubMed Google Scholar
• da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R . (2005). Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65: 10686–10691.
  Article CAS PubMed Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
  Article CAS PubMed Google Scholar
• Davies M, Hennessy B, Mills GB . (2006). Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 7: 2243–2261.
  Article CAS PubMed Google Scholar
• Davies SP, Reddy H, Caivano M, Cohen P . (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95–105.
  Article CAS PubMed PubMed Central Google Scholar
• de Bono JS, Bellmunt J, Droz JP, Miller K, Zugmaier G, Sternberg C et al. (2005). An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naive patients (pts) with hormone refractory prostate cancer (HRPC). ASCO Meeting Abstracts 22 (16S) (abstract 4609).
• Doi T, Ohtsu A, Saijo N, Takiuchi H, Ohhashi Y, Weber D et al. (2005). A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody ‘EMD72000 (Matuzumab)’ administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies. ASCO Meeting Abstracts 22 (16S) (abstract 3077).
• Dominguez C, Powers DA, Tamayo N . (2005). p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 8: 421–430.
  CAS PubMed Google Scholar
• Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL et al. (2006). Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 12: 1251–1259.
  Article CAS PubMed Google Scholar
• Duesbery N, Vande Woude G . (2006). BRAF and MEK mutations make a late entrance. Sci STKE 2006: pe15.
  Article PubMed Google Scholar
• Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH et al. (2001). Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci USA 98: 4089–4094.
  Article CAS PubMed PubMed Central Google Scholar
• Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900–5909.
  Article CAS PubMed Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581–586.
  Article CAS PubMed PubMed Central Google Scholar
• Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M et al. (2005). Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts), (16S) (abstract LBA4510).
• Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA . (2006). HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140: 8–16.
  Article PubMed CAS Google Scholar
• Friess T, Scheuer W, Hasmann M . (2005). Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 11: 5300–5309.
  Article CAS PubMed Google Scholar
• Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ . (1997). A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 272: 18926–18931.
  Article CAS PubMed Google Scholar
• Gibson TB, Ranganathan A, Grothey A . (2006). Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6: 29–31.
  Article PubMed Google Scholar
• Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A et al. (2002). Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 8: 3611–3621.
  CAS PubMed Google Scholar
• Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer MA, Fleming GF et al. (2005). Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. ASCO Meeting Abstracts 22 (16S): (abstract 5051).
• Grandis JR, Sok JC . (2004). Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102: 37–46.
  Article CAS PubMed Google Scholar
• Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D et al. (2006). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103: 57–62.
  Article CAS PubMed Google Scholar
• Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott Jr CI, Doyle D et al. (2006). HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140: 1–7.
  Article PubMed CAS Google Scholar
• Hahn O, Stadler W . (2006). Sorafenib. Curr Opin Oncol 18: 615–621.
  Article CAS PubMed Google Scholar
• Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.
  Article CAS PubMed Google Scholar
• Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. . (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198–5202.
  CAS PubMed Google Scholar
• Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J et al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999–1006.
  Article CAS PubMed Google Scholar
• Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822.
  Article CAS PubMed Google Scholar
• Hynes J, Leftheri K . (2005). Small molecule p38 inhibitors: novel structural features and advances from 2002-2005. Curr Top Med Chem 5: 967–985.
  Article CAS PubMed Google Scholar
• Hynes NE, Lane HA . (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341–354.
  Article CAS PubMed Google Scholar
• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55: 10–30.
  Article PubMed Google Scholar
• Jimeno A, Hidalgo M . (2006). Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta 1766: 217–229.
  CAS PubMed Google Scholar
• Johnson GL, Lapadat R . (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911–1912.
  Article CAS PubMed Google Scholar
• Karin M . (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431–436.
  Article CAS PubMed Google Scholar
• Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L et al. (2002). Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 99: 14398–14403.
  Article CAS PubMed PubMed Central Google Scholar
• Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I et al. (2006). Genotype–phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 43: 401–405.
  Article CAS PubMed PubMed Central Google Scholar
• Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K et al. (1999). Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem 274: 8383–8390.
  Article CAS PubMed Google Scholar
• Kolch W . (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827–837.
  Article CAS PubMed Google Scholar
• Kortum RL, Lewis RE . (2004). The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol Cell Biol 24: 4407–4416.
  Article CAS PubMed PubMed Central Google Scholar
• Lacouture ME . (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6: 803–812.
  Article CAS PubMed Google Scholar
• Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL et al. (2007). A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109: 1387–1394.
  Article CAS PubMed PubMed Central Google Scholar
• Lee P, Wallace E, Yeh T, Poch G, Litwiler K, Pheneger T et al. (2004). ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in murine xenograft models correlates with decreased ERK phosphorylation. AACR Meeting Abstracts (abstract 897).
• Leung KF, Baron R, Seabra MC . (2006). Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res 47: 467–475.
  Article CAS PubMed Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23: 5281–5293.
  Article CAS PubMed Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
  Article CAS PubMed Google Scholar
• Lyons JF, Wilhelm S, Hibner B, Bollag G . (2001). Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8: 219–225.
  Article CAS PubMed Google Scholar
• Lyssikatos J, Yeh T, Wallace E, Marsh V, Bernat B, Gross S et al. (2004). ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectivity. AACR Meeting Abstracts 45: (abstract 896b).
• Malumbres M, Barbacid M . (2003). RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459–465.
  Article CAS PubMed Google Scholar
• Manning AM, Davis RJ . (2003). Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2: 554–565.
  Article CAS PubMed Google Scholar
• McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M . (1995). Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 9: 1953–1964.
  Article CAS PubMed Google Scholar
• Mendelsohn J, Baselga J . (2006). Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369–385.
  Article CAS PubMed Google Scholar
• Mercer KE, Pritchard CA . (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653: 25–40.
  CAS PubMed Google Scholar
• Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN et al. (2004). Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int J Oncol 24: 1181–1188.
  CAS PubMed Google Scholar
• Michaelson D, Ali W, Chiu VK, Bergo M, Silletti J, Wright L et al. (2005). Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell 16: 1606–1616.
  Article CAS PubMed PubMed Central Google Scholar
• Mitin N, Rossman KL, Der CJ . (2005). Signaling interplay in Ras superfamily function. Curr Biol 15: R563–574.
  Article CAS PubMed Google Scholar
• Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M et al. (1996). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 93: 15481–15484.
  Article CAS PubMed PubMed Central Google Scholar
• Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O et al. (2005a). Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16: 1688–1694.
  Article CAS PubMed Google Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S et al. (2005b). Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Meeting Abstracts 22 (16S): (abstract 1).
• Moy B, Goss PE . (2006). Lapatinib: Current status and future directions in breast cancer. Oncologist 11: 1047–1057.
  Article CAS PubMed Google Scholar
• Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ et al. (2006). Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312: 1211–1214.
  Article CAS PubMed Google Scholar
• Neckers L . (2006). Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 6: 1163–1171.
  Article CAS PubMed Google Scholar
• Nelson MH, Dolder CR . (2006). Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40: 261–269.
  Article CAS PubMed Google Scholar
• Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A et al. (2006). Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38: 294–296.
  Article CAS PubMed Google Scholar
• O'Neill LA . (2006). Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5: 549–563.
  Article CAS PubMed Google Scholar
• Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192–1197.
  Article CAS PubMed Google Scholar
• Orth K, Palmer LE, Bao ZQ, Stewart S, Rudolph AE, Bliska JB et al. (1999). Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector. Science 285: 1920–1923.
  Article CAS PubMed Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL . (2006). How many drug targets are there? Nat Rev Drug Discov 5: 993–996.
  Article CAS PubMed Google Scholar
• Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M et al. (2003). Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol 89: 129–133.
  Article CAS PubMed Google Scholar
• Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
  Article PubMed PubMed Central CAS Google Scholar
• Parulekar WR, Eisenhauer EA . (2004). Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96: 990–997.
  Article CAS PubMed Google Scholar
• Perez-Soler R, Saltz L . (2005). Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23: 5235–5246.
  Article PubMed Google Scholar
• Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE . (2002). Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.
  Article CAS PubMed Google Scholar
• Reid TS, Terry KL, Casey PJ, Beese LS . (2004). Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 343: 417–433.
  Article CAS PubMed Google Scholar
• Repasky GA, Chenette EJ, Der CJ . (2004). Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 14: 639–647.
  Article CAS PubMed Google Scholar
• Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456–4462.
  Article CAS PubMed Google Scholar
• Rini BI . (2006). Sorafenib. Expert Opin Pharmacother 7: 453–461.
  Article CAS PubMed Google Scholar
• Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS et al. (2006). Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311: 1287–1290.
  Article CAS PubMed Google Scholar
• Rowinsky EK . (2006). Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol 24: 2981–2984.
  Article CAS PubMed Google Scholar
• Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D et al. (2004). Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10: 7244–7251.
  Article CAS PubMed Google Scholar
• Salazar R, Tabernero J, Rojo F, Jimenez E, Montaner I, Casado E et al. (2004). Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). ASCO Meeting Abstracts 22 (14S): (abstract 2002).
  Article Google Scholar
• Sausville EA, Burger AM . (2006). Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66: 3351–3354 discussion 3354.
  Article CAS PubMed Google Scholar
• Scaltriti M, Baselga J . (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268–5272.
  Article CAS PubMed Google Scholar
• Schreck R, Rapp UR . (2006). Raf kinases: oncogenesis and drug discovery. Int J Cancer 119: 2261–2271.
  Article CAS PubMed Google Scholar
• Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G et al. (2006). Germline KRAS mutations cause Noonan syndrome. Nat Genet 38: 331–336.
  Article CAS PubMed Google Scholar
• Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J . (2001). Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 15: 981–994.
  Article CAS PubMed PubMed Central Google Scholar
• Schulze A, Nicke B, Warne PH, Tomlinson S, Downward J . (2004). The transcriptional response to Raf activation is almost completely dependent on mitogen-activated protein kinase kinase activity and shows a major autocrine component. Mol Biol Cell 15: 3450–3463.
  Article CAS PubMed PubMed Central Google Scholar
• Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810–816.
  Article CAS PubMed Google Scholar
• Sebolt-Leopold JS, English JM . (2006). Mechanisms of drug inhibition of signalling molecules. Nature 441: 457–462.
  Article CAS PubMed Google Scholar
• Sebolt-Leopold JS, Herrera R . (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937–947.
  Article CAS PubMed Google Scholar
• Sebti SM, Der CJ . (2003). Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3: 945–951.
  Article CAS PubMed Google Scholar
• Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP . (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412–2421.
  Article CAS PubMed Google Scholar
• Sharp S, Workman P . (2006). Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95: 323–348.
  Article CAS PubMed Google Scholar
• Sharpless NE, Depinho RA . (2006). The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741–754.
  Article CAS PubMed Google Scholar
• Shaw RJ, Cantley LC . (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424–430.
  Article CAS PubMed Google Scholar
• Shields JM, Pruitt K, McFall A, Shaub A, Der CJ . (2000). Understanding Ras: ‘it ain't over ‘til it's over’. Trends Cell Biol 10: 147–154.
  Article CAS PubMed Google Scholar
• Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R et al. (2004). In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202: 336–340.
  Article CAS PubMed Google Scholar
• Singer G, Oldt III R, Cohen Y, Wang BG, Sidransky D, Kurman RJ et al. (2003). Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484–486.
  Article CAS PubMed Google Scholar
• Skobeleva N, Menon S, Weber L, Golemis GA, Khazak V . (2007). In vitro and in vivo synergy of MCP compounds with MAPK pathway- and microtuble-targeting inhibitors. Mol Cancer Ther In Press.
• Smith RA, Dumas J, Adnane L, Wilhelm SM . (2006). Recent advances in the research and development of RAF kinase inhibitors. Curr Top Med Chem 6: 1071–1089.
  Article CAS PubMed Google Scholar
• Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.
  Article CAS PubMed Google Scholar
• Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525–526.
  Article CAS PubMed Google Scholar
• Sumimoto H, Hirata K, Yamagata S, Miyoshi H, Miyagishi M, Taira K et al. (2006). Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 118: 472–476.
  Article CAS PubMed Google Scholar
• Tabernero J, Rojo F, Jimenez E, Montaner I, Santome L, Guix M et al. (2003). A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. ASCO Meeting Abstracts 22: (abstract 770).
• Thompson N, Lyons J . (2005). Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5: 350–356.
  Article CAS PubMed Google Scholar
• Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS et al. (2002). A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8: 2530–2535.
  CAS PubMed Google Scholar
• van Steensel MA, Vreeburg M, Peels C, van Ravenswaaij-Arts CM, Bijlsma E, Schrander-Stumpel CT et al. (2006). Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 15: 731–734.
  Article CAS PubMed Google Scholar
• Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O et al. (2004). Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175–184.
  Article CAS PubMed Google Scholar
• Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ . (2003). The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 278: 21938–21943.
  Article CAS PubMed Google Scholar
• Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855–867.
  Article CAS PubMed Google Scholar
• Wellbrock C, Karasarides M, Marais R . (2004). The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875–885.
  Article CAS PubMed Google Scholar
• Wiley HS . (2003). Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 284: 78–88.
  Article CAS PubMed Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109.
  Article CAS PubMed Google Scholar
• Winter-Vann AM, Casey PJ . (2005). Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 5: 405–412.
  Article CAS PubMed Google Scholar
• Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James SJ et al. (2003). Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 100: 6529–6534.
  Article CAS PubMed PubMed Central Google Scholar
• Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z et al. (2003). Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 9: 1266–1268.
  Article CAS PubMed Google Scholar
• Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A . (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236–1243.
  CAS PubMed Google Scholar
• Yarden Y . (2001). The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3–S8.
  Article CAS PubMed Google Scholar
• Yeh T, Wallace E, Lyssikatos J, Winkler J . (2004). ARRY-142886, a potent and selective MEK inhibitor: II) Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf. AACR Meeting Abstracts 45: (abstract 3889).
• Yoon S, Seger R . (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21–44.
  Article CAS PubMed Google Scholar
• Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M et al. (2000). A genome-wide survey of RAS transformation targets. Nat Genet 24: 144–152.
  Article CAS PubMed Google Scholar